Remepy is harnessing the power of our digital world to improve drugs. We combine medicine with tailored software applications, triggering brain mechanisms that positively influence our immune system, increasing drug efficacy and safety. We offer our platform to pharma companies, enabling them to launch patentable software-drug combinations.
Location: Israel
Total raised: $51M
Founded date: 2022
Investors 5
| Date | Name | Website |
| - | StageNext ... | stagenext.... |
| - | TechAviv F... | techaviv.c... |
| 29.11.2022 | TechAviv F... | fund.techa... |
| 11.09.2024 | PsyMed Ven... | psymed.ven... |
| 27.01.2023 | Supernode ... | supernode.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.08.2026 | Series A | $36M | M Ventures |
| 07.05.2024 | Seed | $15M | - |
Mentions in press and media 18
| Date | Title | Description |
| 20.08.2026 | Remepy Raises $36 Million Series A, Bringing Total Funding To $62 Million As Parkinson’s Hybrid Drug Heads Toward Phase III | Remepy has raised $36 million in Series A financing to advance its pipeline of Hybrid Drugs, including global Phase III development of Hybridopa for Parkinson’s disease, bringing the company’s total capital raised to $62 million. The round ... |
| 16.08.2026 | Remepy Secures $36 Million Series A, Propelling Hybrid Drug Innovation | Remepy, a New York biotech, secured $36 million in Series A funding. Total raised hits $62 million. O.G. Venture Partners and M Ventures led the round. Funds drive Hybrid Drug development and Parkinson's program, Hybridopa, into global Phas... |
| 16.08.2026 | Venture Capital Shifts to Hard Tech, Deep Impact | Venture capital shifts focus. Hard tech and vertical AI dominate recent funding. Form Energy leads with $750M for iron-air grid batteries, addressing critical energy infrastructure needs. Lovable secures $400M for AI coding, showcasing dema... |
| 12.08.2026 | Remepy Snares $36 Million Series A | NEW YORK, NY, Remepy, the pioneer of Hybrid Drugs, announced the closing of a $36 million Series A financing round led by O.G. Venture Partners and M Ventures. >> Click here for more funding data on Remepy >> To export Remepy f... |
| 12.08.2026 | Venture Capital & Startup Funding Roundup, August 12, 2026: Coatue, Franklin Templeton, CapitalG, Menlo Ventures, Sequoia Capital & More | The day’s deals underscore one clear theme: venture capital continues to pour into fundamental infrastructure and vertical AI playbooks, not consumer fluff. A massive $750M infusion into Form Energy’s iron-air battery plant leads the charge... |
| 12.08.2026 | Remepy Raises $36 Million Series A To Advance Hybridopa Phase III And Hybrid Drug Pipeline | Remepy has raised $36 million in Series A funding to expand its Hybrid Drug pipeline, accelerate pharmaceutical partnerships, and fund global Phase III development of Hybridopa for Parkinson’s disease. The financing brings the company’s tot... |
| 12.08.2026 | Remepy raises $36 million Series A as it prepares AI-driven Parkinson’s treatment for Phase III | The Israeli company’s Hybridopa program has shown improvements in motor and non-motor symptoms in Phase IIa trials, while a new partnership with Merck is expanding its approach into rare tumors. |
| 12.08.2026 | Remepy Raises $36M in Series A Funding | Remepy, a NYC-based provider of a platform for hybrid drugs that combine prescription medicines with personalized, AI-driven therapeutic apps, raised $36M in Series A funding. The round was led by O.G. Venture Partners and M Ventures, with ... |
| 10.11.2025 | Mamdani win rattles Israeli business community in New York City | On October 29, Israeli tech entrepreneurs gathered on a lower Manhattan podium to ring the opening bell of the New York Stock Exchange’s trading floor, in a show meant to celebrate the innovations and contributions of Israeli-founded startu... |
| 10.10.2024 | 97212 Ventures: Interview With Founder Eyal Bino About The Israel-Based Venture Firm | 97212 Ventures is a seed fund exclusively focused on investing in top early stage Israeli startups committed to building category defining companies in NYC. Pulse 2.0 interviewed 97212 Ventures founder Eyal Bino to learn more about the firm... |
Show more